Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
Dentsply Sirona (XRAY) reported Q3 2025 results with net sales of $904 million versus $951 million a year ago and an operating loss of $218 million. The quarter included $262 million of goodwill and intangible asset impairments, leading to a net loss of $427 million, or $2.14 per share.
Sales declined in the United States to $291 million from $374 million, while Europe rose to $382 million from $347 million. Segment mix showed Essential Dental Solutions at $357 million and Orthodontic and Implant Solutions at $205 million; Wellspect Healthcare increased to $83 million from $72 million.
Year to date, net sales were $2.719 billion versus $2.888 billion, with $497 million of impairments and a net loss of $452 million. Cash from operating activities was $134 million year to date, ending cash was $363 million. Long‑term debt was $2,017 million and current debt was $378 million. Goodwill decreased to $1,270 million from $1,597 million, and total equity was $1,478 million.
DENTSPLY SIRONA (XRAY) furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 under Item 2.02. The company notes this information is being furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities or incorporation by reference unless specifically referenced.
DENTSPLY SIRONA (XRAY) announced a leadership change. On October 31, 2025, the company determined that Matthew E. Garth will no longer serve as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun a search for its next CFO. The filing states Mr. Garth’s departure was not due to any disagreement regarding financial statements, internal controls, or operations.
Effective upon Mr. Garth’s departure, Daniel T. Scavilla, the company’s President and CEO and a director, was appointed as interim principal financial officer for SEC reporting. The company noted no new compensatory arrangements for Mr. Scavilla related to these additional responsibilities, and no related‑party relationships were disclosed.
DENTSPLY SIRONA (XRAY) reported an insider transaction by President & CEO and Director Daniel T. Scavilla. On 10/10/2025, he acquired 223.681 restricted stock units (RSUs) at $0, recorded as dividend equivalents on existing RSUs. Following this, his beneficial ownership stands at 17,698.73 shares, held directly.
The filing notes these RSU dividends carry the same vesting schedule as the underlying awards, and each RSU converts to one share of common stock upon vesting.
DENTSPLY SIRONA (XRAY) filed a Form 4 for an executive equity accrual. On 10/10/2025, the SVP, Chief Supply Chain Office reported 972.381 shares of common stock acquired at $0, credited as dividends on restricted stock units that vest with the underlying awards and convert 1:1 into common stock.
The filing also reports 40.5116 phantom stock units under the SERP acquired at $11.98, each economically equivalent to one share and payable in stock upon termination of employment. Following these entries, direct ownership stands at 124,187.521 common shares and 3,072.9326 phantom stock units.
DENTSPLY SIRONA (XRAY) director reported an equity accrual. On 10/10/2025, the reporting person acquired 179.449 units at $0, reflecting dividends credited on previously awarded RSUs that carry the same vesting terms. Each RSU converts to common stock on a 1:1 basis.
Following this transaction, beneficial ownership stood at 48,005.925 on a direct basis. These credits represent routine dividend equivalents tied to outstanding RSUs rather than open‑market purchases.
DENTSPLY SIRONA (XRAY) director filed a Form 4 reporting RSU dividend equivalents. On 10/10/2025, the reporting person acquired 286.094 restricted stock units as dividends on existing RSUs at a price of $0. Following this transaction, beneficial ownership stands at 40,897.4765 shares, held directly.
The company states these are dividends on RSUs awarded to the reporting person, delivered as additional RSUs that carry the same vesting terms as the underlying awards. Each RSU converts to common stock on a 1:1 basis, and the dividend RSUs vest simultaneously with the related RSUs.
DENTSPLY SIRONA (XRAY): Form 4 insider transaction by a director. On 10/10/2025, 310.397 shares of common stock were acquired at $0 as dividends on restricted stock units credited to a Family Partnership. Following this, beneficial holdings were 24,357.397 shares indirect by Family Partnership, 82,301.434 shares direct, and 21,000 shares indirect by a Gregory Lucier IRA.
On 10/14/2025, the reporting person made a gift (Code G) of 17,200 non‑qualified stock options with a $12.96 exercise price to a Family Partnership. These options are exercisable beginning 08/08/2026 and expire on 08/08/2035. The filing notes the gift and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
DENTSPLY SIRONA (XRAY) director reported routine equity accruals. On 10/10/2025, the reporting person acquired 359.576 shares of common stock at $0 as dividend equivalents on previously granted RSUs. Following this transaction, directly held common stock totaled 28,451.376 shares.
The filing also shows an acquisition of 123.3618 units of phantom stock under the Directors' Deferred Compensation plan at a derivative price of $11.98. Phantom stock represents the economic equivalent of common stock and becomes payable in shares upon the director’s termination of service. After this accrual, the director held 11,743.5642 phantom stock units.
Notes clarify these were dividend-related accruals for RSUs and phantom stock, with RSUs converting to common stock on a 1:1 basis and phantom stock payable in common stock upon termination.
DENTSPLY SIRONA (XRAY) reported insider equity accruals. Officer Richard C. Rosenzweig received 766.323 shares of common stock on 10/10/2025 at $0 (code A) from dividends on previously awarded RSUs that vest with the underlying awards. Following the transaction, directly held common stock was 85,183.54 shares.
He also acquired 80.9848 shares of phantom stock under the Supplemental Executive Retirement Plan at a derivative price of $11.98, bringing directly held phantom units to 6,142.9981. Each RSU and phantom unit is equivalent to one share of common stock, with phantom stock payable upon termination of employment.